FDA Chief Targets Kickback Safe Harbor To Trim Drug Prices
The U.S. Food and Drug Administration's leader on Thursday signaled that the Trump administration's campaign to reduce drug prices will target an Anti-Kickback Statute safe harbor for controversial rebates that drugmakers...To view the full article, register now.
Already a subscriber? Click here to view full article